Just substitute KNWN for DCOM in that article : "DexCom, Inc. is a medical device manufacturer that makes continuous blood glucose monitoring devices for patients with diabetes. We believe that DexCom’s device is a superior method for monitoring blood sugar compared with finger sticks (the traditional method). We also believe that DexCom’s market opportunity is large–its core market consists of the 3.2 million insulin intensive patients in the U.S. plus another 3 million to 5 million insulin intensives outside the U.S. The company’s stock rose after it reported significantly higher sales and profits in the fourth quarter of 2019, driven by strong demand for the company's G6 device. Although we think DexCom's growth may be moderately impacted in the near term by the COVID-19 pandemic, we continue to believe the company has a long runway for growth."